In contrast, there is a strong evidence suggesting that treatment with sodium glucose cotransporter- 2 (SGLT-2) inhibitors positively affects cardiovascular and renal outcome in patients with T2DM [217,218,219]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.